These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 25735320)

  • 21. The effect of tumor volume and its change on survival in stage III non-small cell lung cancer treated with definitive concurrent chemoradiotherapy.
    Koo TR; Moon SH; Lim YJ; Kim JY; Kim Y; Kim TH; Cho KH; Han JY; Lee YJ; Yun T; Kim HT; Lee JS
    Radiat Oncol; 2014 Dec; 9():283. PubMed ID: 25498887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression-Free Survival and Time to Progression as Real Surrogate End Points for Overall Survival in Advanced Breast Cancer: A Meta-Analysis of 37 Trials.
    Li L; Pan Z
    Clin Breast Cancer; 2018 Feb; 18(1):63-70. PubMed ID: 28818493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis.
    Johnson KR; Ringland C; Stokes BJ; Anthony DM; Freemantle N; Irs A; Hill SR; Ward RL
    Lancet Oncol; 2006 Sep; 7(9):741-6. PubMed ID: 16945769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review.
    Hotta K; Kato Y; Leighl N; Takigawa N; Gaafar RM; Kayatani H; Hirata T; Ohashi K; Kubo T; Tabata M; Tanimoto M; Kiura K
    PLoS One; 2015; 10(3):e0121211. PubMed ID: 25775395
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer.
    Hamada T; Nakai Y; Isayama H; Yasunaga H; Matsui H; Takahara N; Mizuno S; Kogure H; Matsubara S; Yamamoto N; Tada M; Koike K
    Eur J Cancer; 2016 Sep; 65():11-20. PubMed ID: 27451020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation Between Surrogate End Points and Overall Survival in a Multi-institutional Clinicogenomic Cohort of Patients With Non-Small Cell Lung or Colorectal Cancer.
    Kehl KL; Riely GJ; Lepisto EM; Lavery JA; Warner JL; LeNoue-Newton ML; Sweeney SM; Rudolph JE; Brown S; Yu C; Bedard PL; Schrag D; Panageas KS;
    JAMA Netw Open; 2021 Jul; 4(7):e2117547. PubMed ID: 34309669
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individual- and trial-level surrogacy in colorectal cancer.
    Buyse M; Burzykowski T; Michiels S; Carroll K
    Stat Methods Med Res; 2008 Oct; 17(5):467-75. PubMed ID: 18285439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progression-free survival as a surrogate endpoint for median overall survival in metastatic colorectal cancer: literature-based analysis from 50 randomized first-line trials.
    Giessen C; Laubender RP; Ankerst DP; Stintzing S; Modest DP; Mansmann U; Heinemann V
    Clin Cancer Res; 2013 Jan; 19(1):225-35. PubMed ID: 23149819
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials.
    Sidhu R; Rong A; Dahlberg S
    Clin Cancer Res; 2013 Mar; 19(5):969-76. PubMed ID: 23303214
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer.
    Hotta K; Suzuki E; Di Maio M; Chiodini P; Fujiwara Y; Takigawa N; Ichihara E; Reck M; Manegold C; Pilz L; Hisamoto-Sato A; Tabata M; Tanimoto M; Shepherd FA; Kiura K
    Lung Cancer; 2013 Jan; 79(1):20-6. PubMed ID: 23164554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of post-progression survival in lung cancer.
    Imai H; Kaira K; Minato K
    Thorac Cancer; 2017 Sep; 8(5):379-386. PubMed ID: 28627767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
    Sohn HS; Kwon JW; Shin S; Kim HS; Kim H
    J Clin Pharm Ther; 2015 Dec; 40(6):661-71. PubMed ID: 26573867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression-free survival assessed per immune-related or conventional response criteria, which is the better surrogate endpoint for overall survival in trials of immune-checkpoint inhibitors in lung cancer: A systematic review and meta-analysis.
    Zhu GL; Yang KB; Tang SQ; Peng L
    Cancer Med; 2021 Dec; 10(23):8272-8287. PubMed ID: 34668660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis.
    Zhou F; Jiang T; Ma W; Gao G; Chen X; Zhou C
    Lung Cancer; 2015 Aug; 89(2):203-11. PubMed ID: 26115839
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials.
    Han K; Ren M; Wick W; Abrey L; Das A; Jin J; Reardon DA
    Neuro Oncol; 2014 May; 16(5):696-706. PubMed ID: 24335699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of randomized controlled trials and surrogacy of progression-free survival in advanced/metastatic urothelial cancer.
    Liang F; Zhang S; Wang Q; Li W
    Crit Rev Oncol Hematol; 2018 Oct; 130():36-43. PubMed ID: 30196910
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review.
    Hotta K; Kiura K; Fujiwara Y; Takigawa N; Hisamoto A; Ichihara E; Tabata M; Tanimoto M
    PLoS One; 2011; 6(11):e26646. PubMed ID: 22114662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer.
    Nygaard AD; Garm Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Lung Cancer; 2013 Mar; 79(3):312-7. PubMed ID: 23238036
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.